|Bid||73.410 x 300|
|Ask||73.420 x 200|
|Day's Range||73.120 - 73.770|
|52 Week Range||63.760 - 82.100|
|PE Ratio (TTM)||7.75|
|Dividend & Yield||2.08 (2.86%)|
|1y Target Est||N/A|
Mylan (MYL) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
This week, companies like Regeneron (REGN) and Ionis provided updates on their pipeline while Gilead announced priority review for its HIV drug.
Gilead Sciences' CEO hints that buying a biotech with an oncology focus might not happen. Here's what this could mean for the big biotech.